Kellie Mclaughlin

TESARO Inc (NASDAQ: TSRO) fell as much as 9.8 percent Friday on news that Johnson & Johnson (NYSE: JNJ) suspended the enrollment of their shared phase 2 niraparib trial for prostate cancer. A Johnson & Johnson spokesperson told Benzinga the temporary hold isn't related to safety, and...